Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Control-IQ+ automated insulin delivery technology from Tandem Diabetes Care cleared by FDA for people with type 2 diabetes.

Transplanting insulin-producing cells along with engineered blood-vessel-forming cells has successfully reversed type 1 ...

Childhood cancer treatments, specifically total body irradiation, were associated with increased risk of developing diabetes among cancer survivors.

Tandem Diabetes Care announced that the FDA cleared its Control-IQ+ automated insulin delivery algorithm for people with type ...

Researchers at The University of Colorado Anschutz Medical Campus and colleagues at Massachusetts General Hospital, have ...

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings tomorrow after the bell. Here’s ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

Adults with disabilities, especially moderate to severe, have a higher prevalence of diabetes than the general population in the United States.